Literature DB >> 3987175

Single-dose ceftriaxone kinetics in the newborn.

U B Schaad, W L Hayton, K Stoeckel.   

Abstract

Ceftriaxone kinetics were characterized after a single, 2-minute, intravenous infusion of 50 mg/kg to 20 sick infants 1 to 8 days old who weighed 1.78 to 4.36 kg. Plasma binding parameters could be determined by equilibrium dialysis in 16 of the infants, in whom kinetic parameters for free ceftriaxone in plasma were also determined. Compared with corresponding values in adults, the elimination t1/2 was longer in infants (19 and 8.4 hours) because of reduced total systemic clearance (4.48 and 8.51 ml/min/m2). The apparent steady-state volume of distribution was of the same order in infants and adults (5,130 and 5,350 ml/m2). Both renal and nonrenal clearance of free ceftriaxone were reduced in infants, but these decreases were partially offset by an increased free fraction; plasma binding affinity and capacity constants for infants were about half the adult values. The mean fraction of dose excreted unchanged in urine was estimated at 70% in the neonates and 46% in adults. There were no clinically significant correlations between the kinetic parameters and either age since birth or age since conception. The fraction of free ceftriaxone in plasma inversely correlated with age since conception and was lower in female infants, which decreased the systemic clearance and volume of distribution of total drug in the female infants compared with the male infants. Values for the volume of distribution and clearance parameters were not related to body size (weight or body surface area). From our results, a ceftriaxone dosage of 50 to 100 mg/day is recommended during the first week of life for newborn infants who weigh between 1.8 and 4.4 kg. Impaired renal function may require a reduction in dosage.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987175     DOI: 10.1038/clpt.1985.82

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Ceftriaxone in the treatment of meningitis, gonococcal infections and other serious bacterial infections. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1990-03-01       Impact factor: 8.262

Review 2.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 3.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  beta-lactam antibiotics in the treatment of neuroborreliosis in children: preliminary results.

Authors:  M M Millner; G H Thalhammer; P Dittrich; K D Spork; M Brunner; A Georgopoulos
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

Review 5.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

7.  Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.

Authors:  Trevor N Johnson; Amin Rostami-Hodjegan; Geoffrey T Tucker
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Evaluation of a potential clinical interaction between ceftriaxone and calcium.

Authors:  Emily Steadman; Dennis W Raisch; Charles L Bennett; John S Esterly; Tischa Becker; Michael Postelnick; June M McKoy; Steve Trifilio; Paul R Yarnold; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

9.  Characteristics of ceftriaxone binding to immunoglobulin G and potential clinical significance.

Authors:  H Sun; M S Chow; E G Maderazo
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

10.  Age-associated changes in ceftriaxone pharmacokinetics.

Authors:  W L Hayton; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.